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Abstract
Background: CHARGE syndrome is an autosomal dominant disorder, characterized by ocular Coloboma,
congenital Heart defects, choanal Atresia, Retardation, Genital anomalies and Ear anomalies. Over 90 % of
typical CHARGE patients are mutated in the CHD7 gene, 65 %–70 % of the cases for all typical and suspected
cases combined. The gene encoding for a protein involved in chromatin organization. The mutational spectrum
include nonsense, frameshift, splice site, and missense mutations. Large deletions and genomic rearrangements
are rare.
Case presentation: We report here on a 5.9 years old male of Moroccan origin displaying classic clinical features
of CHARGE syndrome. Using CGH array and NGS analysis we detected a microdeletion (184 kb) involving the
promoter region and exon 1 of CHD7 gene and the flanking RAB2 gene.
Conclusion: The present observation suggests that deletion limited to the regulatory region of CHD7 is sufficient
to cause the full blown CHARGE phenotype. Different size of deletions can result in different phenotypes, ranging
from a milder to severe CHARGE syndrome; this is based on a combination of major and minor diagnostic
characteristics, therefore to a more variable clinical features, likely due to the additive effect of other genetic
imbalances. MLPA and CGH techniques should be considered in the diagnostic protocol of individuals with a
clinical suspect of CHARGE syndrome
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Background
CHARGE (MIM# 214800) is the acronym of an auto-
somal dominant genetic condition, characterized by ocu-
lar Coloboma, congenital Heart defects, choanal Atresia,
Retardation (of growth and/or of development), Genital
anomalies and Ear anomalies (abnormal pinnae and/or
hearing loss, abnormal semicircular canals) [1]. CHD7
gene has been causally linked to this disorders. The
embryologic expression of the gene involves many tis-
sues, including the eye, inner ear, and olfactory bulb cells.
In addition it is widely expressed in undifferentiated
neuroepithelium and in neural crest mesenchyme, and,
at the end of the first trimester, in dorsal root ganglia,
cranial nerves and ganglia, and auditory, pituitary and
nasal tissues, as well as in neural retina [2]. Typical
CHARGE patients are mutated in CHD7 gene in over 90
% of the cases [3], 65 %–70 % for all typical and milder
phenotypes combined [4–7]. The CHD7 gene codes for
one member of a family of proteins thought to play a role
in the organization of chromatin, belonging to the chro-
modomain helicase DNA binding domain family of ATP-
dependent chromatin remodeling enzymes [8]. Members
of this family share a unique combination of functional
domains consisting of two N-terminal chromodomains,
followed by a SWI2/SNF2-like ATPase/helicase domain
and a DNA binding domain [9, 10]. It is assumed that
CHD protein complexes affect chromatin structure and
gene expression, thus playing an important role in regu-
lating embryonic development. The CHD7 protein most
likely controls gene expression by chromatin remodelling.
Chromatin remodelling is the dynamic modification of
chromatin architecture, allowing the access of condensed
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genomic DNA to the regulatory transcription machinery
proteins. Gene expression is lowered in the presence of
tight DNA packaging.
CHARGE syndrome is caused by heterozygous muta-
tions, including nonsense mutations (44 %), frameshift
mutations (34 %), splice site mutations (11 %) and mis-
sense mutations (8 %) [11]. Deletions and genomic rear-
rangements occur in 3% of the cases. Variants expected
to lead to a truncated protein (nonsense and frameshift
mutations and deletions) are considered to be patho-
genic as a consequence of haploinsufficiency [12].
We report here on a male patient affected by CHARGE
syndrome, heterozygous for a deletion involving the
promoter region and exon 1 of the CHD7 gene and the
contiguous RAB2 gene.
Case presentation
The patient, a male of Moroccan origin, is the first
child of healthy unrelated patients. Family history was
unremarkable. At birth, the mother was 22 years old,
the father 26. The baby was born at the 41 week of an
uneventful gestation. Birth weight was 2740 g, length
47 cm, head circumference 32.5 cm. Apgar scores were
7 and 8 at 1 and 5 minutes. Neonatal period was com-
plicated by respiratory distress. Congenital heart defect
was diagnosed in the first day of life. Two-Dimensional
color-Doppler echocardiography showed patent ductus
arteriosus (PDA) and retroesophageal right subclavian
artery. PDA was treated by interventional catheterization.
Bilateral vesico-ureteric refluxes was diagnosed by renal
ultrasound and cystography, and operated endoscopically
at age 1 and 2 years. Ophthalmological examination dem-
onstrated bilateral ocular coloboma of iris, retina and
optic nerve and right eye microphthalmia. Horizontal bi-
lateral nystagmus was also present. Brain-stem-evoked
audiometry showed profound bilateral sensorineural hear-
ing loss, prompting cochlear implants positioning at 18
months of age. Hypoplastic semicircular canals were diag-
nosed by temporal bone CT-scan. Cerebral ultrasound
and electroencephalogram were normal.
Developmental milestones were delayed. The patient
sat at 15 months, and started walking at 28 months.
Language was absent. Feeding difficulties were recorded,
resulting in growth deficiency. Bilateral cryptorchidism
was operated at 2 years.
At time of last evaluation the patient was 5.9 years old.
Weight was 13,9 kg, height 102 cm, head circumference
46.5 cm (all paramerters below the 3rd centile). Clinical
features included microcephaly, facial palsy, right micro-
phthalmia, down-slanting palpebral fissures, prominent
nose with round tip, everted upper lip, multiple dental
caries, micrognathia, cupped asymmetric and low-set
ears, dysplastic toe nails.
Materials and methods
Array comparative genomic hybridization (array-CGH) was
performed with the Agilent Human Genome CGH
Microarray 60K kit (Agilent Technologies, Santa Clara, CA,
U.S.A.). This platform is a 60-mer oligonucleotide-based
micro- array that allows a genome-wide survey and mo-
lecular profiling of genomic aberrations with a resolution of
about 41 kb. DNA was extracted from peripheral blood
using QIAampH DNA Blood Kit (QIAGEN Sciences,
Germantown, MD, U.S.A.) according to the manufacturer’s
instructions (Agilent Oligonucleotide Array-Based CGH for
Genomic DNA Analysis – Version 7.2, July 2012). The
array was analyzed through the Agilent Scanner and
the Feature Extraction software (v10.7.3.1) and Agilent
Genomic Workbench 7.0.4. Bioinformatic analysis was
carried out by consulting the Database of Genomic
Variants BioXRT [http://projects.tcag.ca/variation/].
Gene content analysis in the deleted segment was
carried out by using UCSC database NCBI37/hg19
(http://www.genome.ucsc.edu).
Next Generation Sequencing analysis was performed
on DNA extracted from peripheral blood of the pa-
tient. The CHD7 gene is included in a panel of genes
responsible for eye anomalies and was analysed by
Targeted resequencing, using a uniquely customized
design (TruSeq® Custom Amplicon; Illumina, San Diego,
CA) with the MiSeq® sequencing platform (Illumina,
San Diego, CA). TruSeq Custom Amplicon (TSCA) is
a fully integrated DNA-to-data solution, including on-
line probe design and ordering through the Illumina
website sequencing assay automated data analysis and
offline software for reviewing results. (According to
NCBI gene: NG_007009.1; NM_ 017780; NP_060250.2).
Results
Array-CGH analysis disclosed a deletion spanning about
184 kb of genomic DNA, including RAB2 gene (Ras-
associated protein RAB2) and upstream region of CHD7
(chromodomain helicase DNA binding protein 7) gene,
including 5’UTR and untraslated exon one. Array-CGH
analysis in the proband mother was normal (Fig. 1),
while the father was unavailable for the study.
NGS analysis showed a variant in intron 2 (rs7836586),
heterozygosity of this variant excluded deletion in this
region. A fine mapping of the deletion revealed that
one breakpoint was upstream of RAB2 gene (8q12.1-
61.421.463) while the second breakpoint was within
intron 1 (8q12.2-61,605,551). The variant reported in
the VCF output file has been evaluated for the cover-
age and the Qscore and visualized via Integrative
Genome Viewer (IGV) [13, 14]. This analysis showed
that ATG was excluded from the deletion, but im-
portant regulatory regions were lacking, including
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untranslated exon 1, the 5-UTR region and probably
the promoter region.
Conclusion
CHARGE syndrome is an autosomal dominant disorder,
with most cases being de novo. The mutational spectrum
of CHD7 in patients affected by CHARGE syndrome is
variable, including nonsense, frameshift, splice site and
missense mutations, deletions and genomic rearrange-
ments [11]. Rarely deletions affect the CHD7 gene, only
a few cases having been reported so far: deletion of
single or multiple exons, deletion of the entire gene or
larger deletion that include CHD7 gene and flanking
genes. Using MLPA, Wincent et al. (2008) [15] reported
microdeletions in 17 % of their patients. Palumbo et al.
(2013) [16] reviewed published patients with 8q12 dele-
tions affecting multiple genes flanking CHD7 (Table 1).
It has been questioned if differently sized deletions can
account for variable clinical expression. All known pa-
tients, but two, displayed CHARGE syndrome. Two sub-
jects manifested severe growth retardation and failure to
thrive, hypertrichosis, gastro-esophageal reflux, and neu-
rodevelopmental defects (patients 2 and 3 in the Table 1).
It has been highlighted that the clinical features of these
patients in some respect overlapped those of individuals
with the 8q12 duplication phenotype [23–25]: develop-
mental delay, sensorineural deafness and a congenital
renal and heart defect. This rather specific recurrent pat-
tern of congenital anomalies associated with overlapping
duplications of the genomic region containing CHD7
suggests that the phenotype may be the result of abnor-
mal CHD7 dosage.
Potential molecular mechanisms underlying phenotypic
variability of the delete CHARGE patients include deletion
size, gene contents of the missing region, polymorphisms
or mutations in the hemizygous allele, different genomic
background or environmental factors. A dosage sensitive
role of some genes, including CA8, RAB2A, CLVS1 and
CHD7 has been also suggested [16]. The CA8 gene product
lacks carbonic anhydrase activity (i.e., the reversible hydra-
tion of carbon dioxide). The gene product continues to
carry a carbonic anhydrase designation based on clear se-
quence identity to other members of the carbonic anhy-
drase gene family. The absence of CA8 gene transcription
in the cerebellum of the lurcher mutant in mice with a
neurologic defect suggests an important role for this acata-
lytic form. CLVS1 (Clavesin 1) is a Protein Coding gene;
diseases associated with CLVS1 include Duane Retraction
Fig. 1 CGH array results; a) proband: deletion of five probes at level of RAB2A and CHD7; b) mother: normal
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syndrome. GeneOntology annotations related to this gene
include transporter activity and phosphatidylinositol-3,5-
bisphosphate binding.
The present patient, presenting with a CHARGE syn-
drome, has a unique deletion, spanning about 184 kb of
genomic DNA, including RAB2 gene and a small part of
CHD7. RAB2A (RAB2A, member RAS oncogene family)
is a protein-coding gene, previously associated with vagi-
nal cancer and vaginitis. The protein encoded by this gene
belongs to the Rab family, members of which are small
molecular weight guanosine triphosphatases (GTPases)
containing highly conserved domains involved in GTP
binding and hydrolysis. Rabs are membrane-bound pro-
teins, affecting vesicular fusion and trafficking. This
protein is a resident of pre-Golgi intermediates, and
is required for protein transport from the endoplas-
mic reticulum (ER) to the Golgi complex. To identify
the role of Rab2 in membrane trafficking, Tisdale et
al (1992) [26] generated site-directed Rab2 mutants.
These mutations inhibited protein transport from the
ER to the Golgi and indicate that Rab2 is required
for ER to Golgi trafficking. Spliced transcript variants
encoding different isoforms are known (provided by
RefSeq, Oct 2011). To date, there is no evidence of
any link between RAB2 mutations and CHARGE syn-
drome, but we can not exclude a role of the deletion
on the final phenotype of our patient.
Most of the phenotype of our patient is likely due to
the deletion of the 5’UTR region and exon 1 of CHD7
with consequent block of gene translation. Sequencing
analysis did not reveal any additional pathogenic variant
in CHD7 gene, but some polymorphisms acting as pos-
sible phenotypic modifiers (heterozygous SNPs: rs78
36586, rs4540437, rs10448027, rs6471902, rs138947382,
rs7005873, rs7844902 and rs139382713).
In conclusion, small deletions including the CHD7 gene
result in CHARGE syndrome. Larger deletions can be
associated with mild to severe CHARGE syndrome or a
different disorder resulting from the additive effect of
flanking genes. The present patient shows that deletion of
region upstream of CHD7 gene is sufficient per se to cause
CHARGE syndrome. The increased number of patients
diagnosed with 8q12 deletions suggests that loss of single
exons is probably less rare than previously considered in
these patients. Accordingly, sequencing analysis, MLPA
and CGH techniques should be all considered in the diag-
nostic protocol of subjects with a clinical suspicion of
CHARGE syndrome [3].
Consent
Clinical investigations and genetic analyses were ap-
proved by the institutional scientific board of Bambino
Gesù Children Hospital and conducted in accordance
with the Helsinki Declaration. Written informed con-
sent was obtained from the parents for publication of
this case report. A copy of the written consent is
available for review by the Editor of this journal.
Table 1 Clinical features of reported patients with 8q12 microdeletions encompassing the CHD7 gene, including the present case
Clinical feature 1 2 3 4 5 6 7 8 9
Sex F F F M M M M F M
Ocular coloboma + + + + + + - - +
Choanal atresia + - - - - - - - -
External ear anomaly + + + - + + + + +
Hearing deficit + + - + nr + - - +
Cleft lip/palate - - - - - + - - -
Larynx malformation - - - - - + - - -
Facial palsy + - - - + + - - +
Congenital heart defect + + + + + + + + +
Genital anomaly nr - + + + + - - +
Urinary malformation - - - - - + - - -
Temporal bone malformation - + nr nr - + - - +
Growth deficiency - + + nr - + - - +
Developmental delay + + + nr nr + - - +
Phenotype C C C C C C No C No C C
Genetic imbalance t(6;8)(6p8p;6q8q) Del8q12 Del8q11.2-q13 Del ex1 Del ex4 Del CHD7 Del8q12 Del8q12.1q12.3 Del RAB2-5’UTR/
ex1 CHD7
1: [17]; 2: [18]; 3: [19–21]; 4-5-6: [15]; 7: [22]; 8: [11]; 9: Present patient
C : CHARGE nr : not reported
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